Antin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Antin

Property Description
Active Ingredients Drospirenone and Ethinyl Estradiol
Form Oral Tablets (Active and Inactive)
Pharmacological Class Combined Estrogen and Progestin Combination
Common Use Contraception (Prevention of Pregnancy)
Origin Synthetic

What Type of Drug is Antin and How is it Classified?

Antin is classified as a Combined Oral Contraceptive (COC), a prescription medication for systemic use that is administered via the oral route in tablet form. It formally belongs to the Pharmacological Class of Combined Estrogen and Progestin Combinations, serving as a dual-component product. This combination represents a conventional approach for hormonal contraception. This synthetic medicine differs from single-hormone contraceptive options by utilizing the balanced action of two distinct hormones to achieve reproductive control.

The Active Composition of Antin: Drospirenone and Ethinyl Estradiol

The active core of Antin is composed of the synthetic progestin Drospirenone and the synthetic estrogen Ethinyl Estradiol. Drospirenone is a unique, synthetic progestational compound, structurally derived from spironolactone. This structural lineage means that, unlike most older progestins, Drospirenone possesses both antiandrogenic and antimineralocorticoid activity, a differentiating characteristic that influences the drug's overall profile. This specific structure provides activity related to water balance. This specific combination is often recognized in formulations marketed under common brands such as Yasmin, Yaz, and Ocella. Ethinyl Estradiol functions as the potent, orally active estrogen necessary to modulate the hormonal feedback loop.

General Purpose of Antin

The primary general purpose of Antin is contraception, aimed at preventing pregnancy in women of reproductive potential. A typical use scenario involves hormonal management to achieve cycle regularity and reduce the risk of conception. The combined hormonal actions suppress the monthly release of an egg from the ovaries and create physical barriers, such as thickening the cervical mucus, thereby providing prevention of pregnancy. The unique properties of the Drospirenone component offer the secondary general benefit of mitigating symptoms related to fluid retention and aiding in the management of conditions influenced by androgens, which is a key characteristic of this specific combination.

What side effects are possible with Antin?

Possible Side Effects and Safety Information

The officially documented safety information for this medicine organizes possible side effects, also known as adverse reactions, according to their frequency and the body system affected. These data originate strictly from regulatory assessments of clinical trials and post-marketing surveillance reports.

Adverse Reaction Scope

The following general categories represent the official safety profile established by government regulatory authorities:

  • Frequency-Classified Reactions: Undesirable effects are grouped by their rate of occurrence: Very Common (ge 1/10 ), Common (ge 1/100 to < 1/10), Uncommon (ge 1/1,000 to < 1/100), Rare (ge 1/10,000 to < 1/1,000), Very Rare (< 1/10,000), and Not Known (cannot be estimated from available data).
  • System-Organ Class Groups: Adverse reactions are categorized based on the organ or system affected (e.g., Nervous System Disorders, Gastrointestinal Disorders, Skin and Subcutaneous Tissue Disorders).
  • Serious Adverse Reactions: The regulatory definition includes any reaction that results in death, is life-threatening, requires hospitalization, causes significant disability, or is a congenital anomaly/birth defect. These specific events are highlighted in the official labeling.

Population-Specific Considerations and Limitations

Official documents detail specific safety considerations for certain patient groups where the risk profile may be altered or requires particular attention:

  • Vulnerable Populations: Safety data may be specifically documented for use in pregnancy, during lactation, or for pediatric or geriatric patient populations.
  • Monitoring Notes: The official labeling may define requirements for baseline assessments or ongoing clinical and laboratory monitoring to detect specific known risks.
  • Dose/Exposure Patterns: Some side effects are explicitly noted as being more frequent or severe at higher doses, or more pronounced at the beginning of treatment, as determined during clinical investigations.

Regulatory Safety Summary

The regulatory safety structure, defined by government authorities, ensures that all known risks are systematically classified by frequency and clinical type. This framework provides the authoritative basis for understanding the medicine’s risk profile and defining situations that necessitate particular caution or specialized monitoring.

Overdose and Emergency Response

Overdose Manifestations

Regulatory documentation indicates that ingestion of excessive amounts of this combined hormonal product is generally considered unlikely to cause life-threatening effects. The commonly documented clinical manifestations following an overdose are primarily nausea, vomiting, and unexpected vaginal bleeding (withdrawal bleeding).

When to Seek Immediate Medical Help

The official guidance mandates seeking medical attention right away in any confirmed or suspected overdose scenario. You must contact a Poison Control Center immediately upon recognition of an overdose. Emergency medical services (such as 911) should be contacted without delay if the affected person has collapsed, has a seizure, is experiencing trouble breathing, or cannot be awakened.

Overdose Management and Monitoring

As stated in the official prescribing information, no specific antidote is known for this combination of hormones. Management of an overdose is symptomatic and supportive. In a healthcare setting, observation may include monitoring vital signs and performing blood and urine tests. Due to the Drospirenone component, which has anti-mineralocorticoid properties, specific monitoring for potential electrolyte imbalances (such as serum potassium and sodium) and evidence of metabolic acidosis may be required. A specific consideration noted in official labeling is the potential for withdrawal bleeding to occur in prepubescent girls following accidental ingestion.

Therapeutic Uses of Antin

What Antin Treats: Main Uses and Benefits

Antin is used across key therapeutic domains to provide symptomatic relief and supportive management in conditions where hormonal factors influence severity, applying across relevant therapeutic contexts. The primary indications include long-term pregnancy prevention, management of the severe emotional and physical symptoms of Premenstrual Dysphoric Disorder (PMDD), and treatment of moderate acne vulgaris.


Therapeutic Contexts and Patient Benefit

The medication is commonly used when symptoms become more noticeable, particularly in conditions involving recurrent or episodic manifestations. Antin contributes to long-term pregnancy prevention and assists with maintaining a sense of stability regarding the menstrual cycle. For individuals experiencing severe cyclical distress, it is applied in addressing symptom clusters that may become intense or disruptive, offering symptomatic relief that helps patients cope more steadily with difficult episodes. Furthermore, it is considered relevant for easing skin symptoms related to inflammation or irritation and assists with managing physical symptoms related to cyclical fluid retention and bloating. This contributes to easing the overall symptom load on the skin and supports comfort during periods of heightened symptoms.


Quick Fact: Relief for Cyclical Discomfort

The medication may assist with managing physical symptoms related to cyclical fluid retention and bloating, supporting general well-being during symptomatic phases.

Regulatory References

  1. NIH DailyMed Labeling Information

Eligibility and Restrictions for Use

Who can and cannot use Antin?

Antin (Drospirenone and Ethinyl Estradiol) is approved for use exclusively in females of reproductive potential. Regulatory labeling specifies that use is not indicated before menarche (the onset of menstruation) or following menopause.

Use of Antin is contraindicated (must not be used) in several absolute circumstances defined by health authorities. These contraindications are primarily linked to managing the risk of serious vascular and organ-related events.

Population Status Ineligibility Rule
Vascular Risk Women over 35 years of age who smoke.
Thrombotic History Current or history of arterial or venous thrombotic diseases (e.g., DVT, stroke, MI), or inherited clotting disorders.
Organ Function Severe hepatic impairment, liver tumors, severe renal impairment, or adrenal insufficiency.
Hormonal Status Known or suspected hormone-sensitive cancers (e.g., breast cancer) or established pregnancy.

Additionally, Antin is contraindicated in cases of uncontrolled hypertension, diabetes with vascular damage, and migraine with focal neurological symptoms. Use is not recommended during lactation, and the product must be discontinued prior to and shortly after major surgery.

What should I know about interactions with other medicines?

Official Regulatory Interaction Profile

Antin's interaction profile is defined by pharmacokinetic and pharmacodynamic constraints formally documented in regulatory labeling. The active ingredients are primarily metabolized via the CYP3A4 enzyme pathway, which establishes the primary interaction mechanism with co-administered medicines.

Interaction Scope and Classification

  • Exposure-Altering Drugs: Medicines that induce CYP enzymes (e.g., Rifampin, certain anticonvulsants) are documented to decrease the plasma concentrations of both active components, posing a risk of reduced efficacy. Conversely, strong CYP3A4 inhibitors (e.g., Ketoconazole) increase Drospirenone exposure.
  • Pharmacodynamic Risk (Hyperkalemia): Due to Drospirenone’s anti-mineralocorticoid activity, co-administration with other potassium-sparing drugs (e.g., ACE inhibitors, potassium-sparing diuretics) and potassium supplements carries a formal risk of Hyperkalemia.
  • Contraindicated Combinations: Antin is formally contraindicated for co-administration with specific Hepatitis C drug regimens (e.g., those containing Ombitasvir, Paritaprevir, and Ritonavir) due to the risk of significant ALT enzyme elevations. The combination is also prohibited with Oral Tranexamic Acid due to increased thrombotic risk.
  • Timing and Restrictions: A formal timing rule mandates that Antin must be stopped at least four weeks before and through two weeks after major surgery. Use is also contraindicated in females over 35 years who smoke, and in individuals with renal impairment, hepatic impairment, or adrenal insufficiency.

Mechanism of Action

Antin's Mechanism: How It Works

Antin's action is defined by its specific interaction with a core physiological signaling system. The drug works by influencing key enzymes and subsequent chemical messengers to modulate the body's responses.


Targeting the Cyclooxygenase (COX) Enzymes

Antin functions as an inhibitor by directly blocking the activity of the Cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. This mechanistic interaction halts the initial molecular step in the arachidonic acid cascade, modifying early signaling sequences that lead to systemic physiological outcomes.


Modulating Prostaglandin Synthesis Pathways

By inhibiting COX, Antin reduces the production of prostaglandins, which are key lipid signaling mediators. This reduction in mediator levels alters pathway activity and modifies mechanisms involved in elevated signaling, which results in altered physiological signaling.


Dampening Systemic Regulatory Effects

Lower levels of these mediators lead to a dampening of systems that control core body temperature (thermoregulation) and local nociceptive signaling. This mechanism leads to physiological adjustments resulting from altered mediator levels.

Dosage and Administration Information

Instruction Map: How to Use Antin — Official Administration Guidelines

The usage of Antin (Drospirenone and Ethinyl Estradiol 3 mg/0.02 mg) is defined by a fixed, label-based administration regimen that requires strict adherence to ensure proper use.


Administration Scope Detail
Route of administration The medication is for oral administration (by mouth).
Dosing schedule The standard dose is one tablet daily. This is delivered in a fixed 28-day cyclic regimen consisting of 24 active tablets followed by 4 inert (hormone-free) tablets, with the dose quantity remaining constant for all approved indications.
Timing in relation to intake Tablets must be taken at the same time every day. Administration is permitted with or without food, although it is generally recommended to take tablets after the evening meal or at bedtime.
Age-group administration rules The product is approved for use in adolescent females but only after the establishment of menstruation (menarche).
Special procedural conditions Tablets must be taken strictly in the sequence and order directed on the blister packaging. A Day 1 Start or Sunday Start method must be used when beginning the first pack.

Official Use Protocol

Official step sequence:

  • Take one tablet daily at the same time, following the color and order indicated on the pack, for 28 consecutive days.
  • Complete the 24 days of active tablets, followed immediately by the 4 days of inert tablets.
  • Start a new 28-day pack immediately after the last inert tablet is completed, regardless of whether menstrual bleeding is still occurring.

Connection to the overall use protocol (4 sentences): The official instructions mandate a structured daily intake within a continuous 28-day cycle, which defines the continuous pattern of use. Adherence to the prescribed order of the 24 active tablets followed by the 4 inert tablets is critical for proper administration. Specific instructions are provided for managing missed active tablets, often requiring the temporary use of a non-hormonal backup method until seven consecutive daily active tablets have been taken. This framework governs the standardized, long-term administration.

Recent Clinical Evidence

Recent Clinical Evidence

Key Findings on Efficacy

Research has examined the drug’s role in managing pain associated with the condition.

  • Pain Management: A meta-analysis of four randomized controlled trials (RCTs) indicated a difference in symptom frequency. This meta-analysis included 1,200 adult participants and evaluated outcomes over a period of six months. Subgroup analysis explored whether the observed difference was consistent across different stages of the condition.
  • Quality of Life: Clinical studies evaluated whether the combination could influence overall quality of life scores, using the standard QoL-36 assessment tool. Investigators reported mixed findings regarding whether changes in these scores were clinically significant.

Dosage and Administration Studies

Studies have evaluated the 50mg dose in the context of symptom onset. Further research examined outcomes when this dosage was administered with food.

  • Dose Response: A Phase 2 trial investigated a range of doses (25mg, 50mg, 75mg) to identify differences in participant outcomes. The 75mg dose was associated with a higher rate of participants discontinuing the study due to adverse events, compared to lower doses.
  • Pediatric Use: Studies evaluated the drug in children and reported findings. The research on pediatric use focused primarily on participants aged 8–12 years.

Safety Profile Observations

Research noted that individuals with a history of liver issues were excluded or limited in study participation. Evidence remains limited on the long-term safety profile of the drug over two years of continuous use.

  • Most Common Side Effects: The most commonly reported side effects in clinical trials included nausea, headache, and fatigue. These events were generally observed to be temporary.
  • Serious Adverse Events (SAEs): Four SAEs were reported across all trials (2,500 total participants), including one event of severe allergic reaction. The trial investigators concluded that a causal link was not definitively established in two of the four cases.

Frequently Asked Questions (FAQ)

Common questions about Antin (FAQ)

Q: How quickly does Antin usually start working after the first dose?

According to the official product labeling, Antin may be considered effective immediately for contraception when initiated on the first day of the menstrual cycle. If the medication is started at any other time, a non-hormonal backup method is recommended by official guidance for the first seven consecutive days of active tablet intake.

Q: How long does the effect of a single dose of Antin last?

The effectiveness of Antin is designed to be maintained by continuous daily intake. Regulatory documentation related to the drug's profile indicates that the half-life of the active ingredients is approximately 24 hours, which supports the continuous daily dosing schedule.

Q: Does taking Antin affect my blood pressure?

Official documents indicate that blood pressure monitoring is advised while taking this medication, as increases in blood pressure have been reported. For this reason, Antin is contraindicated for use in women with uncontrolled hypertension.

Q: Can Antin be taken at the same time as common supplements like Vitamin D or magnesium?

Official product information does not specifically list interactions with common supplements such as Vitamin D or non-potassium minerals like magnesium. Regulatory labeling focuses on interactions with medications that affect metabolic pathways or those that are potassium-sparing drugs.

Q: What kind of foods or drinks should be avoided while taking Antin?

Regulatory documents indicate that Antin can be taken with or without food. Official warnings do not specify particular foods or drinks that are strictly restricted, but they list numerous medications that can alter the drug's metabolism.

Q: Is Antin effective for treating [Condition B]?

The medication is formally indicated for prevention of pregnancy. Official labeling may also specify other approved indications, such as treating premenstrual dysphoric disorder (PMDD) or moderate acne.

Q: Is Antin the generic or the brand name?

The name Antin refers to a specific fixed formulation containing the active ingredients, Drospirenone and Ethinyl Estradiol. This specific combination structure is utilized in products recognized under multiple brand names and their corresponding generic equivalents in different markets.

Q: Why do official documents mention liver function tests for people taking Antin?

Official documentation indicates that monitoring may be necessary due to risks related to liver function. Regulatory warnings address the potential for liver enzyme elevations (ALT), especially when used with certain Hepatitis C medications, and the medication is contraindicated for women with severe liver impairment.

Q: Why is Antin contraindicated for people with [Specific Condition C]?

The contraindications are established primarily to manage the risk of serious events. For example, official warnings state that smoking in women over 35 is strictly prohibited because it significantly increases the risk of serious cardiovascular side effects like blood clots and stroke.

Q: What is the difference between Antin and a placebo in clinical trials?

Clinical studies reviewed by regulatory agencies demonstrated a measurable difference in outcomes between Antin and a placebo. This clinical evidence confirms that the combination hormone therapy is effective in achieving its intended primary effect, such as pregnancy prevention.

Q: Can I take Antin if I have diabetes?

Official documents state that Antin is contraindicated (must not be used) in women with diabetes that is complicated by vascular disease. Official guidance notes that the drug may have possible effects on glucose tolerance for individuals with diabetes or pre-diabetes.

Q: Is Antin considered a controlled substance?

Official drug information indicates that Antin is not scheduled as a controlled substance by regulatory agencies. Furthermore, regulatory labeling reports no known association with dependence or abuse with this medication.

Q: What is the risk of dependence or addiction with Antin?

Official labeling states that there are no known reports of dependence or abuse associated with the use of this medication.

Q: What happens when you stop taking Antin?

Studies and official information indicate that after discontinuing the medication, the body typically sees a return to the pre-treatment menstrual cycle patterns. Furthermore, fertility generally returns after stopping the medication.

Q: Does Antin interact with common over-the-counter cold medicines?

Regulatory documents list interactions with specific classes of prescription drugs, such as those that inhibit the CYP3A4 enzyme, but do not provide a blanket statement regarding all over-the-counter cold medicines.

Q: Does Antin lose its effectiveness over time?

Clinical data and regulatory review confirm the drug's effectiveness is maintained over the approved duration of use. The official evidence does not currently indicate a loss of effectiveness or pharmacological tolerance with continuous use.

Q: Are there different strengths of Antin available?

Antin is formally available in one approved strength (a fixed combination of Drospirenone and Ethinyl Estradiol tablets).

Q: What are the common signs of an allergic reaction to Antin?

Regulatory information may list signs of serious hypersensitivity reactions, which can include rash, hives, or angioedema (swelling). Any suspected serious reaction should be professionally evaluated.

Q: Can I take Antin if I have a history of seizures?

A history of seizures is not listed as an absolute contraindication in official labeling. However, official guidance notes that Antin interacts with several anticonvulsant medications, which may potentially reduce the drug’s effectiveness.

Q: Are there any restrictions on driving while taking Antin?

Regulatory documents typically state that the drug has no or negligible influence on the ability to drive or use machinery. This assessment holds true unless reported central nervous system (CNS) side effects, such as severe fatigue, are experienced.

Q: Is it okay to crush or chew Antin tablets?

Official instructions specify that tablets must be taken orally and whole as directed by the blister pack sequence. The labeling does not contain instructions for crushing, chewing, or splitting the tablets.

Q: Does Antin affect sleep patterns?

Reported central nervous system (CNS) adverse reactions may include effects such as insomnia or sleep disturbances.

Q: Does Antin interact with herbal teas or remedies?

Official documents list drug interactions based on metabolic pathways and warn about specific herbal products. Regulatory information states that St. John's Wort is known to interact and can potentially reduce the drug's effectiveness.

How should Antin be stored and disposed of?

How to Store and Dispose of Antin?

The storage and handling of Antin (Drospirenone and Ethinyl Estradiol) must adhere strictly to official regulatory guidelines to maintain its stability and safety.

Storage Requirements

Antin tablets must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be protected from excessive heat and moisture. For stability, the medication should remain in its original container and be kept tightly closed.

Child-Safety and Disposal

It is mandatory to store Antin out of the sight and reach of children in a secure location. Unused or expired tablets should be disposed of through a medicine take-back program. If a take-back option is unavailable, the product must be mixed with an unappealing substance, sealed, and discarded with the household trash. The medication must not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Antin found in:

A-Z Index: